Accelerate Diagnostics (AXDX) Competitors

Accelerate Diagnostics (NASDAQ:AXDX) and 908 Devices (NASDAQ:MASS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations, community ranking and risk.

Does the media refer more to AXDX or MASS?

In the previous week, Accelerate Diagnostics and Accelerate Diagnostics both had 4 articles in the media. Accelerate Diagnostics' average media sentiment score of 1.44 beat 908 Devices' score of -0.02 indicating that Accelerate Diagnostics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Accelerate Diagnostics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
908 Devices	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer AXDX or MASS?

Accelerate Diagnostics received 336 more outperform votes than 908 Devices when rated by MarketBeat users. Likewise, 59.87% of users gave Accelerate Diagnostics an outperform vote while only 57.58% of users gave 908 Devices an outperform vote.

Company	Underperform	Outperform
Accelerate Diagnostics	Outperform Votes 355 59.87%	Underperform Votes 238 40.13%
908 Devices	Outperform Votes 19 57.58%	Underperform Votes 14 42.42%

Is AXDX or MASS more profitable?

908 Devices has a net margin of -109.11% compared to Accelerate Diagnostics' net margin of -471.83%. Accelerate Diagnostics' return on equity of 0.00% beat 908 Devices' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Accelerate Diagnostics	-471.83%	N/A	-191.66%
908 Devices	-109.11%	-24.60%	-19.23%

Do institutionals and insiders hold more shares of AXDX or MASS?

17.1% of Accelerate Diagnostics shares are owned by institutional investors. Comparatively, 88.1% of 908 Devices shares are owned by institutional investors. 43.6% of Accelerate Diagnostics shares are owned by insiders. Comparatively, 27.7% of 908 Devices shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Which has higher earnings and valuation, AXDX or MASS?

908 Devices has higher revenue and earnings than Accelerate Diagnostics. 908 Devices is trading at a lower price-to-earnings ratio than Accelerate Diagnostics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Accelerate Diagnostics	$12.06M	2.76	-$61.62M	-$2.86	-0.46
908 Devices	$50.23M	1.64	-$36.40M	-$1.77	-1.34

Which has more risk and volatility, AXDX or MASS?

Accelerate Diagnostics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500. Comparatively, 908 Devices has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Do analysts recommend AXDX or MASS?

Accelerate Diagnostics presently has a consensus price target of $1.00, indicating a potential downside of 24.76%. 908 Devices has a consensus price target of $5.33, indicating a potential upside of 125.04%. Given 908 Devices' higher probable upside, analysts clearly believe 908 Devices is more favorable than Accelerate Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Accelerate Diagnostics	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
908 Devices	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Accelerate Diagnostics and 908 Devices tied by winning 9 of the 18 factors compared between the two stocks.